Lead Product(s) : Mebendazole
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Uppsala University | Uppsala University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.
Details : Undisclosed
Product Name : ReposMBZ
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 14, 2018
Lead Product(s) : Mebendazole
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Uppsala University | Uppsala University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mebendazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Yale University | Noguchi Memorial Institute for Medical Research | Ghana Health Service | HopeXchange Medical Center, Ghana | Kintampo Health Research Centre, Ghana
Deal Size : Inapplicable
Deal Type : Inapplicable
Mebendazole Study Against Hookworm Infections in Children and Adolescents in Ghana
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2017
Lead Product(s) : Mebendazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Yale University | Noguchi Memorial Institute for Medical Research | Ghana Health Service | HopeXchange Medical Center, Ghana | Kintampo Health Research Centre, Ghana
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mebendazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2015
Lead Product(s) : Mebendazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mebendazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2014
Lead Product(s) : Mebendazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mebendazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2014
Lead Product(s) : Mebendazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mebendazole
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2013
Lead Product(s) : Mebendazole
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mebendazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Commonwealth Scientific and Industrial Research Organisation, Australia | World Health Organization | Institut Pasteur Cambodia | University of Queensland | Fiocruz | University of Nottingham | University of Yaounde 1 | Ivo de Carneri Foundation | Nationa
Deal Size : Inapplicable
Deal Type : Inapplicable
Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2011
Lead Product(s) : Mebendazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Commonwealth Scientific and Industrial Research Organisation, Australia | World Health Organization | Institut Pasteur Cambodia | University of Queensland | Fiocruz | University of Nottingham | University of Yaounde 1 | Ivo de Carneri Foundation | Nationa
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mebendazole
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase IV
Sponsor : McGill University | Asociacion Civil Selva Amazonica | World Health Organization | Thrasher Research Fund | Canadian Institutes of Health Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2011
Lead Product(s) : Mebendazole
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase IV
Sponsor : McGill University | Asociacion Civil Selva Amazonica | World Health Organization | Thrasher Research Fund | Canadian Institutes of Health Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mebendazole
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety Study of Mebendazole in Children 2 to 10 Years of Age
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 02, 2010
Lead Product(s) : Mebendazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
